iBio, Inc.
Moat Score — iBio, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | iBio holds 16 issued patents and dozens of pending applications around its Epitope Steering AI engine and StableHu generative antibody-optimization tool, giving it a real, if unproven, computational discovery platform. The IP is genuine but covers preclinical-stage science with no approved product yet to validate its commercial value. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Far from having a cost advantage, iBio is a thinly capitalized micro-cap that has repeatedly had to raise cash through highly dilutive pre-funded warrant offerings, including a 71.5-million-share raise priced at $0.699 per warrant in August 2025. It has no manufacturing or commercial scale to drive costs down. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | iBio has no commercial products and therefore no pricing power today; its only near-term revenue is milestone and license payments negotiated bilaterally with AstralBio under an option-and-license structure, not market-based pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | There is a minor data-flywheel effect as more antibody targets are screened through the Epitope Steering and mammalian-display platforms, improving model performance over time, but this is a weak, early-stage effect rather than a defensible network moat. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a partner like AstralBio has exercised a license and begun IND-enabling work on a specific antibody (e.g., IBIO-600's myostatin program), unwinding that relationship mid-program would be costly and slow, but iBio's overall partner base is tiny and concentrated in essentially one counterparty. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The muscle-preserving, obesity-adjacent antibody niche iBio targets is narrow, but it sits adjacent to the much larger and intensely contested GLP-1 and AI-antibody-discovery markets dominated by Eli Lilly, Novo Nordisk, Recursion, and AbCellera, so iBio's scale is not remotely protective against better-funded entrants. |